SNY vs PFE

For growth investors, Sanofi (SNY) is the stronger pick with 5.

5% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Sanofi (SNY) offers the better valuation at 18. 4x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Sanofi (SNY) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sanofi (SNY) is the cheapest at 18.

4x versus Pfizer Inc. at 19. 5x. On forward P/E, Pfizer Inc. is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Sanofi (SNY) delivered a total return of +5.

3%, compared to -11. 3% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: SNY returned +60. 6% versus PFE's +30. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sanofi (SNY) is the lower-risk stock at 0.

51β versus Pfizer Inc. 's 0. 54β — meaning PFE is approximately 6% more volatile than SNY relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sanofi (SNY) is pulling ahead at 5.

5% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Pfizer Inc. grew EPS -3. 5% year-over-year, compared to -7. 3% for Sanofi. Over a 3-year CAGR, SNY leads at 4. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sanofi (SNY) is the more profitable company, earning 16.

7% net margin versus 12. 4% for Pfizer Inc. — meaning it keeps 16. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus 13. 6% for SNY. At the gross margin level — before operating expenses — SNY leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 9. 0x forward P/E versus 10. 4x for Sanofi — 1. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 14. 2% to $50. 00.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 5%, versus 5. 0% for Sanofi (SNY).

For long-horizon retirement investors, Sanofi (SNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

51), 5. 0% yield). Both have compounded well over 10 years (SNY: +60. 6%, PFE: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.